X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SUN PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SUN PHARMA AUROBINDO PHARMA/
SUN PHARMA
 
P/E (TTM) x 18.0 15.9 112.7% View Chart
P/BV x 5.8 3.7 155.8% View Chart
Dividend Yield % 0.4 0.2 173.6%  

Financials

 AUROBINDO PHARMA   SUN PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
SUN PHARMA
Mar-16
AUROBINDO PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5411,201 128.3%   
Low Rs582706 82.4%   
Sales per share (Unadj.) Rs237.5117.5 202.2%  
Earnings per share (Unadj.) Rs33.919.6 172.8%  
Cash flow per share (Unadj.) Rs40.623.8 170.5%  
Dividends per share (Unadj.) Rs2.501.00 250.0%  
Dividend yield (eoy) %0.20.1 224.6%  
Book value per share (Unadj.) Rs120.6130.5 92.4%  
Shares outstanding (eoy) m585.172,406.60 24.3%   
Bonus/Rights/Conversions PREF--  
Price / Sales ratio x4.58.1 55.1%   
Avg P/E ratio x31.348.7 64.4%  
P/CF ratio (eoy) x26.240.1 65.3%  
Price / Book Value ratio x8.87.3 120.4%  
Dividend payout %7.45.1 144.6%   
Avg Mkt Cap Rs m621,0412,294,813 27.1%   
No. of employees `00013.314.7 90.1%   
Total wages/salary Rs m15,50847,971 32.3%   
Avg. sales/employee Rs Th10,457.619,169.8 54.6%   
Avg. wages/employee Rs Th1,167.13,253.0 35.9%   
Avg. net profit/employee Rs Th1,491.63,197.9 46.6%   
INCOME DATA
Net Sales Rs m138,961282,697 49.2%  
Other income Rs m1,6636,170 26.9%   
Total revenues Rs m140,624288,867 48.7%   
Gross profit Rs m32,05683,239 38.5%  
Depreciation Rs m3,92610,135 38.7%   
Interest Rs m2,5684,769 53.8%   
Profit before tax Rs m27,22574,505 36.5%   
Minority Interest Rs m39-11,126 -0.4%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m0-6,852 0.0%   
Tax Rs m7,4449,349 79.6%   
Profit after tax Rs m19,82047,159 42.0%  
Gross profit margin %23.129.4 78.3%  
Effective tax rate %27.312.5 217.9%   
Net profit margin %14.316.7 85.5%  
BALANCE SHEET DATA
Current assets Rs m100,015308,646 32.4%   
Current liabilities Rs m74,759132,477 56.4%   
Net working cap to sales %18.262.3 29.2%  
Current ratio x1.32.3 57.4%  
Inventory Days Days10783 129.5%  
Debtors Days Days11088 124.9%  
Net fixed assets Rs m52,350133,606 39.2%   
Share capital Rs m5852,407 24.3%   
"Free" reserves Rs m67,707266,909 25.4%   
Net worth Rs m70,567314,042 22.5%   
Long term debt Rs m8,47231,167 27.2%   
Total assets Rs m156,994542,196 29.0%  
Interest coverage x11.616.6 69.8%   
Debt to equity ratio x0.10.1 121.0%  
Sales to assets ratio x0.90.5 169.8%   
Return on assets %14.39.6 148.9%  
Return on equity %28.115.0 187.0%  
Return on capital %37.717.8 212.6%  
Exports to sales %51.014.0 364.6%   
Imports to sales %18.83.1 599.9%   
Exports (fob) Rs m70,92739,572 179.2%   
Imports (cif) Rs m26,1938,882 294.9%   
Fx inflow Rs m71,01542,171 168.4%   
Fx outflow Rs m28,79921,583 133.4%   
Net fx Rs m42,21620,588 205.0%   
CASH FLOW
From Operations Rs m17,59667,694 26.0%  
From Investments Rs m-13,801-44,549 31.0%  
From Financial Activity Rs m-198-19,243 1.0%  
Net Cashflow Rs m3,5973,902 92.2%  

Share Holding

Indian Promoters % 54.1 63.7 84.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 5.1 155.0%  
FIIs % 27.7 23.0 120.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 8.3 122.9%  
Shareholders   69,601 133,026 52.3%  
Pledged promoter(s) holding % 8.6 0.5 1,615.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 17, 2017 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS